Table 3.
Predictors of Renal Scarring in Children with an Outcome Renal Scan
| Characteristic at Entry* | Corticosteroid (N=123) | Placebo (N=131) | Odds ratio (95%CI) | P valuea |
|---|---|---|---|---|
| No. of children with renal scarring/total (%) | ||||
| Age | .008 | |||
| < 24 months | 8/95 (8.4) | 10/91 (11.0) | Reference | |
| ≥24 months | 4/28 (14.3) | 12/40 (30.0) | 2.75 (1.30–5.80) | |
| Gender | .39 | |||
| Female | 10/114 (8.8) | 20/120 (16.7) | Reference | |
| Male | 2/9 (22.2) | 2/11 (18.2) | 1.67 (0.52–5.38) | |
| Race | .48 | |||
| White | 6/74 (8.1) | 18/89 (20.2) | 1.33 (0.60–2.95) | |
| Other race | 6/49 (12.2) | 4/42 (9.5) | Reference | |
| Fever duration before presentation | .48 | |||
| <48 hours | 6/68 (8.8) | 10/67 (14.9) | Reference | |
| ≥48 hours | 6/55 (10.9) | 12/64 (18.8) | 1.30 (0.63–2.68) | |
| Fever duration before study product dispensed | .70 | |||
| <48 hours | 6/63 (9.5) | 9/59 (15.3) | Reference | |
| ≥48 hours | 6/60 (10.0) | 13/72 (18.1) | 1.16 (0.56–2.41) | |
| Ibuprofen use within 24 hours of enrollment | .56 | |||
| Yes | 4/66 (6.1) | 14/78 (17.9) | Reference | |
| No | 8/57 (14.0) | 8/53 (15.1) | 1.24 (0.60–2.57) | |
| Ibuprofen use during treatment | .70 | |||
| Yes | 2/31 (6.5) | 5/29 (17.2) | Reference | |
| No | 10/92 (10.9) | 17/102 (16.7) | 1.20 (0.49–2.92) | |
| Leukocyte esterase | .21 | |||
| 1+ or less | 3/18 (16.7) | 3/16 (18.8) | Reference | |
| 2+ | 2/15 (13.3) | 7/28 (25.0) | 1.12 (0.35–3.57) | |
| 3+ | 7/90 (7.8) | 12/87 (13.8) | 0.55 (0.20–1.51) | |
| Infecting organism | .20 | |||
| E. coli | 11/117 (9.4) | 19/121 (15.7) | Reference | |
| Other organism | 1/6 (16.7) | 3/10 (30.0) | 2.18 (0.65–7.27) | |
a
P-values listed correspond to prediction of renal scarring; for this, treatment groups were combined and adjusted for. P values for interaction (not listed) were all non-significant for the above variables.